Cleerly is in the spotlight this week as it secured broader reimbursement for its AI-enabled coronary plaque analysis platform and ramped up education efforts around women’s heart health. The company’s technology leverages non-invasive coronary CT angiography to differentiate between calcified plaque and higher-risk soft plaque that may be missed by traditional tests.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cleerly reports that its offering is now backed by a new Category I CPT code and expanded insurance coverage, making the service reimbursable for a majority of insured lives in the U.S. The improved reimbursement landscape is expected to reduce friction for providers, support higher clinical adoption, and provide more predictable procedure volumes and revenue visibility.
In parallel, Cleerly is promoting a Heart Month webinar on women’s heart health led by preventive cardiologist Dr. Suzanne Steinbaum. The event focuses on sex-specific cardiovascular risk, the role of plaque, diagnostic limitations, and how data can advance equity in coronary artery disease care.
The company is also emphasizing sex-specific insights from its CONFIRM2 cardiovascular study, which includes roughly 50% female participation across 12 countries. Early findings suggest that certain plaque characteristics may be linked to a higher risk of major adverse cardiovascular events in women than in men, underscoring the shortcomings of one-size-fits-all risk models.
Across its communications, Cleerly is positioning its AI-enabled CT and CCTA-based solutions as tools for more tailored and equitable risk assessment, particularly in under-addressed segments like women’s heart health. Combined with growing payer support, these initiatives point to a maturing commercialization environment and could strengthen the company’s long-term role in AI-driven cardiac imaging and decision support.
Overall, the week underscored Cleerly’s progress on both reimbursement and clinical thought leadership, reinforcing its strategic position in digital cardiovascular care.